Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients - Full Text View

Purpose

Chronic pain patients are treated with prescription opioids and many exhibit opioid addiction. Currently, there are no evidence-based guidelines to better manage patients with chronic pain and coexistent opioid addiction. This study compares 6-months buprenorphine and methadone treatment in these patients. The investigators hypothesize that both buprenorphine and methadone treatment will reduce pain and addiction behaviors and increase functioning in these patients.

Condition	Intervention	Phase
Low Back Pain	Drug: Methadone Drug: Buprenorphine/naloxone	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Treatment in Opioid Dependent Chronic Back Pain Patients

Resource links provided by NLM:

MedlinePlus related topics: Back Pain Chronic Pain

Drug Information available for: Methadone Naloxone Methadone hydrochloride Buprenorphine Buprenorphine hydrochloride

U.S. FDA Resources

Further study details as provided by State University of New York at Buffalo:

Primary Outcome Measures:

Analgesia [ Time Frame: monthly for 6 months ] [ Designated as safety issue: No ]
Pain interference will be measured using the Brief Pain Inventory (BPI). Pain severity will be measured using the Visual Analogue Scale (VAS).

Secondary Outcome Measures:

Illicit drug use [ Time Frame: monthly for 6 months ] [ Designated as safety issue: No ]
Illicit drug use will be measured by self-report and urine toxicology.
Cravings [ Time Frame: monthly for 6 months ] [ Designated as safety issue: No ]
Cravings will be assessed using the Visual Analogue Scale (VAS)
Functioning [ Time Frame: monthly for 6 months ] [ Designated as safety issue: No ]
Functioning will be assessed using the Roland-Morris Disability Questionnaire and the Visual Analogue Scale (VAS).
Depression [ Time Frame: monthly for 6 months ] [ Designated as safety issue: No ]
Depression will be assessed using the Beck Depression Inventory.
Treatment retention [ Time Frame: 6 months ] [ Designated as safety issue: No ]


Enrollment:	26
Study Start Date:	February 2012
Study Completion Date:	May 2014
Primary Completion Date:	May 2014 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: Methadone 10-60 mg/day divided by 2-4 times a day	Drug: Methadone 10-60 mg/day divided by 2-4 times a day for 6 months Other Name: Dolophine
Experimental: Buprenorphine/naloxone 4-16 mg/day divided by 2-4 times a day	Drug: Buprenorphine/naloxone 4-16 mg/day divided by 2-4 times a day for 6 months Other Name: Suboxone

Show Detailed Description

Eligibility


Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

have a well-documented chronic pain disorder due to past back surgery,
have a chronic back pain syndrome,
have evidence of opioid addiction,
prior attempt at abstinence-oriented treatment documented by the referring physician,
be able to understand spoken and written English,
reside in Erie or Niagara counties,
have health insurance or other ability to pay for treatment with the approval from patient's primary physician;
have no prior history of methadone or BUP/NLX maintenance treatment since the last surgery,
not be a member of a vulnerable population, including prisoners

Exclusion Criteria:

homeless, or any patient without a "locator" (no means to participate in the follow-up data collection interviews by phone),
inability to give consent,
those with major co-occurring psychiatric disorders,
EKG showing prolonged QT and/or previous cardiac issues,
are taking a medication that is contraindicated with methadone,
medically unstable,
urine positive for cocaine at initial visit,
pregnant women

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01559454

Locations


United States, New York
UB/MD Family Medicine, Inc.
Amherst, New York, United States, 14228

Sponsors and Collaborators

State University of New York at Buffalo

Investigators


Study Director:	Rachel A Rizzo, MPH	University at Buffalo

More Information

No publications provided


Responsible Party:	State University of New York at Buffalo
ClinicalTrials.gov Identifier:	NCT01559454 History of Changes
Other Study ID Numbers:	FMD0600908A
Study First Received:	March 19, 2012
Last Updated:	July 18, 2014
Health Authority:	United States: Institutional Review Board

Keywords provided by State University of New York at Buffalo:


chronic pain opioid dependence methadone buprenorphine substance use disorder

Additional relevant MeSH terms:


Back Pain Nervous System Diseases Neurologic Manifestations Pain Signs and Symptoms Buprenorphine Methadone Analgesics Analgesics, Opioid Antitussive Agents	Central Nervous System Agents Central Nervous System Depressants Narcotic Antagonists Narcotics Peripheral Nervous System Agents Pharmacologic Actions Physiological Effects of Drugs Respiratory System Agents Sensory System Agents Therapeutic Uses

ClinicalTrials.gov processed this record on March 03, 2015